Related Experiment Video
Updated: Jun 18, 2025

An R-Based Landscape Validation of a Competing Risk Model
Published on: September 16, 2022
Assessing the equity and coverage policy sensitivity of financial protection indicators in Europe
Jonathan Cylus1, Sarah Thomson2, Lynn Al Tayara2
1WHO Barcelona Office for Health Systems Financing, Barcelona, Spain; European Observatory on Health Systems and Policies, London, United Kingdom.
Abstract:
Progress towards universal health coverage is monitored by the incidence of catastrophic spending. Two catastrophic spending indicators are commonly used in Europe: Sustainable Development Goal (SDG) indicator 3.8.2 and the WHO Regional Office for Europe (WHO/Europe) indicator. The use of different indicators can cause confusion, especially if they produce contradictory results and policy implications. We use harmonised household budget survey data from 27 European Union countries covering 505,217 households and estimate the risk of catastrophic spending, conditional on household characteristics and the design of medicines co-payments. We calculate the predicted probability of catastrophic spending for particular households, which we call LISAs, under combinations of medicines co-payment policies and compare predictions across the two indicators. Using the WHO/Europe indicator, any combination of two or more protective policies (i.e. low fixed co-payments instead of percentage co-payments, exemptions for low-income households and income-related caps on co-payments) is associated with a statistically significant lower risk of catastrophic spending. Using the SDG indicator, confidence intervals for every combination of protective policies overlap with those for no protective policies. Although out-of-pocket medicines spending is a strong predictor of catastrophic spending using both indicators, the WHO/Europe indicator is more sensitive to medicines co-payment policies than the SDG indicator, making it a better indicator to monitor health system equity and progress towards UHC in Europe.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...
Margin of Error
Hazard Rate
Coefficient of Variation
The coefficient of variation is a practical statistical tool in finance. It allows investors to assess the volatility or...
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...

